SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?


To: zeta1961 who wrote (267)4/12/2005 1:33:18 PM
From: zeta1961Read Replies (2) | Respond to of 802
 
R&R downgrade........................
Apr 12, 2005 (streetinsider) --Rodman & Renshaw downgraded Introgen Therapeutics Inc (Nasdaq: INGN) from Market Perform to Market Underperform. The firm thinks that with pending filings of Taxotere and Erbitux for locally advanced SCCHN, SCCHN may no longer be regarded as a critically unmet medical need. They remain doubtful that INGN's accelerated approval request to the FDA can be granted

[thanks to YMB]

Re: I have a need to know...
by: Monette450 04/12/05 12:31 pm
Msg: 39205 of 39206